A São Paulo team measured changes in five eating behaviors after six months of treatment (n = 66) [1]. The scale asked about habits such as eating for pleasure or in response to emotion. That differs from studies on intrusive thoughts about food, which look at how often thoughts about eating occupy someone’s attention. Both approaches rely on what participants report.
What changed in the questionnaire?
The largest reported reduction in pleasure-driven eating was in the tirzepatide group (Cohen’s dᶻ = 2.06). The reported change in emotional eating was 2.04 in the naltrexone/bupropion group and 1.52 in the semaglutide group [1]. These are standardized changes within each treatment group. They are neither percentages nor estimates of how much better one medication worked than another.
Can the scores guide treatment selection?
The study was retrospective, with no randomized assignment or untreated group. Research on why weight loss varies on GLP-1 treatment puts this cohort in context. The study could describe how early responders’ ratings changed, but it could not predict response from a person’s starting score.